Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD) - LARVOL DELTA

Estimating the Health and Economic Burden of Pneumococcal Diseases Attributable to PCV21 Versus PCV20 or PPSV23 Serotypes Among Adults in Norway. (PubMed, Infect Dis Ther) - "Compared with PCV20 and PPSV23, PCV21 serotypes are associated with a higher health and economic burden in Norway. The inclusion of PCV21 into national vaccine recommendations in Norway can further alleviate the burden associated with PD in adults."

HEOR • Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: University of California, Davis | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns (ASH 2024) - "All 8 centers offered ide-cel while cilta-cel was offered by 6...Other vaccines were given less frequently with Prevnar 20 at 64.3%, Pentavalent (DPT, Hep B, H. influenzae) at 57%, Hep B virus (HBV), RZV, and MCV4 each at 50%. Pneumovax 23 and MMR (live) were recommended by 42.8%, HPV by 35.7%, and VZV (live) by 21.4%...While there are limitations in the generalizability of these practices, these findings demonstrate marked differences in clinical practices across USMIRC centers. Further studies are needed to correlate these practices with downstream infection rates and to allow the development of consensus guidelines for both higher and lower-volume centers."

CAR T-Cell Therapy • Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Hepatitis B • Infectious Disease • Influenza • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • CD4

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns (ASH 2024) - "All centers offered both teclistamab and talquetamab, and 7 also used elranatamab...Other vaccines were used less frequently : Prevnar 20 (33%), Pentavalent (DPT, Hep B, H.influenzae) (27%), Hep B virus (27%), RZV (27%), MCV4 (20%), Pneumovax 23 (20%), HPV (20%), MMR live (20%) and VZV live (6%)...While there are limitations in the generalizability of these practices, these findings demonstrate several areas with varying clinical practices across USMIRC centers. Further studies are needed to correlate these practices with infection rates and to allow development of consensus guidelines for both academic and community centers."

Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Hepatitis B • Infectious Disease • Influenza • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • CD4

Immune Reconstitution and Readiness for Vaccination after Pediatric Allogeneic Bone Marrow Transplantation for Hematologic Malignancies (ASH 2024) - "Adequate response to vaccination was defined as antibody specific IgG levels >0.1 IU/mL for tetanus and >1.3 ug/mL for at least 70% of Pneumovax serotypes measured 4 weeks after dose 3 and 4 of these immunizations, respectively. Patient characteristics and baseline HCT factors assessed for association with readiness for revaccination at 8 months included : age, sex, malignancy type, stem cell source, graft manipulation, GVHD status, and receipt of rituximab...This data will inform immune response based re-immunization protocols and equip clinicians to manage expectations about vaccine timing for patients and caregivers. Further studies are needed in this clinical arena with larger sample sizes where detecting significant associations between potential covariates and vaccine readiness may be more apparent."

Clinical • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Pediatrics • Pneumococcal Infections • Tetanus • Transplantation • CD4

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8. (PubMed, Clin Infect Dis) - P3 | "V116 elicits robust immune responses and is well tolerated in adults 18-64 years of age with conditions associated with an increased risk of PD."

Clinical • Journal • P3 data • Diabetes • Infectious Disease • Metabolic Disorders • Pneumococcal Infections • Pulmonary Disease • Respiratory Diseases

A Complex Case Of Severe Cytopenias In A Child With A Pathogenic CXCR4 Mutation (ACAAI 2025) - "Post-vaccine titers were protective (DTaP, Pneumovax23)...Early recognition is key to ensure appropriate genetic counseling, immunologic monitoring, and surveillance for complications, such as chronic lung disease and malignancies. With limited treatment options for children under 12, especially targeted therapies, close multidisciplinary follow-up is essential in preventing severe complications."

Clinical • Asthma • Autism Spectrum Disorder • Dermatology • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Neutropenia • Primary Immunodeficiency • Pulmonary Disease • Respiratory Diseases • CXCR4 • ELANE

Are we completing the recommended first-line investigations for children with bronchiectasis at Starship Hospital? (WBC 2025) - "Immunoglobulin levels were checked for 147 (90%), vaccine responses for 115 (70%), and pneumococcal serology post-Pneumovax23 for 16 (10%)...Establishing a national pediatric bronchiectasis database would allow ongoing review, identify long-term trends and implement improvement in completing investigations. It will mean we can compare with national paediatric bronchiectasis clinics and collaborate with international registries."

Clinical • Bronchiectasis • Chronic Cough • Cough • Cystic Fibrosis • Developmental Disorders • Genetic Disorders • Immunology • Infectious Disease • Influenza • Pediatrics • Pneumococcal Infections • Pneumonia • Primary Immunodeficiency • Pulmonary Disease • Respiratory Diseases

Supportive Care Gaps in Bronchiectasis Patients with NTM-PD: A Retrospective Study (WBC 2025) - "Pneumococcal vaccination uptake between 2018 and 2023 was similarly low, with 20.7% of bronchiectasis patients with NTMPD receiving either Prevenar 13 or Pneumovax® 23, compared to 15.9% of those without NTM-PD (p = 0.40). While bronchiectasis patients with NTM-PD have more frequent medical encounters, their access to supportive care remains inadequate. The clinical focus on diagnosing NTM and determining antimicrobial treatment needs may inadvertently overshadow supportive care, particularly physiotherapy and vaccinations. This represents a missed opportunity to provide comprehensive, patient-centered management that addresses both the infection and overall lung health."

Retrospective data • Bronchiectasis • Infectious Disease • Influenza • Nontuberculous Mycobacterial Disease • Pneumococcal Infections • Preventive care • Pulmonary Disease • Respiratory Diseases

What About Vaccine-Experienced Younger Adults? Cost-Effectiveness of PCV21 Use in Vaccine-Experienced US Adults Aged 19-64 Years with Underlying Medical Conditions. (PubMed, Am J Prev Med) - "The use of PCV21 in US adults aged 19-64 years with underlying medical conditions can be cost-effective, or cost-saving in most cases, across a wide range of scenarios."

HEOR • Journal • Infectious Disease • Pneumococcal Infections

Primary Antibody Deficiency in Patients With Chronic Rhinosinusitis: A Call for Immunologic Evaluation Prior to Biologic Therapy. (PubMed, Clin Otolaryngol) - "Immunoglobulin testing should be a routine part of the diagnostic work-up in chronic rhinosinusitis before considering biologics, as primary antibody deficiency is an under-recognised but treatable cause of refractory disease."

Journal • Immunology • Otorhinolaryngology • Primary Immunodeficiency • Respiratory Diseases • Sinusitis

Dysfunctional antigenic-induced antibody responses in cystic fibrosis (NACFC 2025) - "To begin to understand the role of CFTR on humoral antibody production in scenarios of autoimmunity and vaccine responsiveness, we utilized the Cftr deficient mouse model to quantify the antigenic antibody response as mice age using the pneumococcal vaccines (Prevnar® and Pneumovax®) and the autoimmunity inducing antigen myelin basic glycoprotein (MOG), which induces experimental autoimmune encephalomyelitis (EAE)... In vivo antigenic responses are significantly different in Cftr deficiency compared to controls, which was impacted by age. Immune dysfunction in CF and host response are likely to be even more pronounced as CF patients live longer with the disease."

CNS Disorders • Cystic Fibrosis • Diabetes • Genetic Disorders • Immunology • Infectious Disease • Metabolic Disorders • Multiple Sclerosis • Pneumococcal Infections • Respiratory Diseases • CFTR • IL10 • IL17A • IL6

Evaluation of T-Cell Responses Following Sequential Vaccination with PCV13 and PPSV23 Against Streptococcus pneumoniae in Patients with Psoriasis. (PubMed, Vaccines (Basel)) - "Immunosuppressive therapy alters vaccination-induced cellular immunity in psoriasis patients. Further research is needed to clarify the mechanisms involved."

Journal • Dermatology • Immunology • Infectious Disease • Pneumococcal Infections • Pneumonia • Psoriasis • IFNG • IL12A • IL17A • IL23A

Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial. (PubMed, JAMA Cardiol) - P3 | "To determine whether pneumococcal vaccination (Pneumovax [Merck Sharp & Dohme Corp]) decreases the composite primary outcome of fatal and nonfatal acute coronary syndrome and ischemic stroke in people at increased risk, with an average follow-up of 7 years after immunization...Results of this randomized clinical trial found that PPV23 did not reduce the rates of fatal and nonfatal acute coronary syndrome and ischemic stroke, although the study was underpowered. ANZCTR Identifier: ACTRN12615000536561."

Adverse events • Clinical • Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Dyslipidemia • Genetic Disorders • Hypertension • Infectious Disease • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Obesity • Pneumococcal Infections

Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial. (PubMed, Lancet HIV) - P3 | "V116 was well tolerated and immunogenic for all 21 serotypes, supporting the use of this vaccine in adults living with HIV. Adults at high risk of pneumococcal disease due to underlying comorbid conditions, such as HIV, might benefit from receiving V116. The serotypes in V116, including the eight unique serotypes, are expected to provide broader protection against pneumococcal disease than currently licensed vaccines."

Journal • P3 data • Human Immunodeficiency Virus • Infectious Disease • Pneumococcal Infections • CD4

Biochemical and Immunological Insights into Capsular Polysaccharide of Streptococcus pneumoniae Serotype 38 (American Type 71)An Emerging Nonvaccine Serotype. (PubMed, ACS Omega) - "Despite the availability of high-valency pneumococcal polysaccharide vaccine of PPSV23 (PNEUMOVAX 23) and conjugate vaccines such as VAXNEUVANCE and PREVNAR 20, nonvaccine serotypes continue to contribute to higher mortality rates...Serotype 38 polysaccharide exhibited immunological cross-reactivity with serotype 5 and serotype 1 polyclonal sera, likely due to a shared epitope region containing a keto sugar component (Sugp) in their repeating units, along with net charge properties similar to serotype 1. These findings revealed novel characteristics of the serotype 38 polysaccharide, including its amino acid composition and net charge, which may contribute to the development of new therapeutics and effective vaccines."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay. (PubMed, Vaccine) - P3 | "To estimate the serotype-specific CAP burden of pneumococcal disease following the introduction of a new 15-valent pneumococcal conjugate vaccine (PCV), V114, a 15-plex serotype-specific urine antigen detection (SSUAD) assay was developed as a tool for surveillance of Streptococcuspneumoniae serotypes...In general, SSUAD positivity appeared unrelated to NP/OP carriage. Our findings suggest SSUAD can support pneumococcal disease surveillance and vaccine effectiveness research, excluding individuals with recent pneumococcal vaccination to avoid false-positives."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) - P4 | N=500 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology • BCL2

A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age. (PubMed, Vaccine) - P3 | "In vaccine-naïve Japanese adults ≥65 years of age, V116 is well tolerated, with a safety profile comparable to PPSV23, and elicits immune responses to all V116 serotypes and the cross-reactive serotype 15B. V116 has the potential to broaden protection against PD in Japan through the inclusion of serotypes responsible for the majority of residual PD in adults."

Clinical • Journal • P3 data • Infectious Disease • Pneumococcal Infections

Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans (clinicaltrials.gov) - P4 | N=45 | Not yet recruiting | Sponsor: VA Sierra Nevada Health Care System | Trial completion date: Feb 2025 ➔ Jun 2027 | Trial primary completion date: Aug 2024 ➔ Jan 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

HEMATOVAC: Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma (clinicaltrials.gov) - P4 | N=160 | Recruiting | Sponsor: Poitiers University Hospital | Trial completion date: Jun 2026 ➔ Nov 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Pneumonia • RARA

A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4). (PubMed, Med) - P3 | "V116 exhibited immunogenicity and safety profiles that were consistent across three manufacturing lots."

Journal • P3 data • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

ENHANCING CARE FOR SICKLE CELL PATIENTS WITH A REAL-TIME LONGITUDINAL PATIENT TRACKING FACILITY WITHIN AN ELECTRONIC PATIENT RECORD SYSTEM (EHA 2025) - "Of 156 patients, 25 left our care between June 2021 and December 2024, resulting in two cohorts of n1=81 and n2=131.Quality indicators were selected based on the Standards for Clinical Care of Adults with SCD in the UK (Sickle Cell Society, 2018).Data collection included hydroxyurea (HU) usage, and urine testing for albumin creatinine clearance (ACR) at each time point. Vaccination records were obtained from primary care for 129 patients (67 (2021) and 114 (2024)).Completeness of vaccination uptake was measured through uptake of influenza (annual), the bexsero (any time) and the pneumovax (within 5 years) of the two timepoints.To assess hospital workload over this period, we recorded cumulative A&E attendances, haematology day unit attendance, clinic appointments, number of nights in hospital and admissions from A&E.A&E attendances rose from 34 (2021) to 62(2024), HDU attendance from 10 (2021) to 81 (2024), number of nights in hospital from 170 (2021) to 355..."

Clinical • Genetic Disorders • Hematological Disorders • Infectious Disease • Influenza • Respiratory Diseases • Sickle Cell Disease

RATES OF INFLUENZA AND PNEUMOCOCCAL VACCINATION AND CORRELATION WITH SURVIVAL IN MULTIPLE MYELOMA PATIENTS: A REAL-LIFE SURVEY (EHA 2025) - "FV was performed in more than 70% of patients while less than a half of patients received PV, in one third of cases with a sub-optimal sequential administration of a polysaccharide vaccine (Pneumovax) followed by a pneumococcal conjugate vaccine (Prevnar13 or Prevnar20). In MM a response to PV is detectable, independently of preexisting hypogammaglobulinemia and possibly of treatment-induced immunodepression, even if a drop in the serum response overtime suggests the need of a dedicated schedule with a multidisciplinary approach, especially in the setting of RRMM patients."

Clinical • Pneumococcal vaccines • CNS Disorders • Depression • Hematological Malignancies • Infectious Disease • Influenza • Multiple Myeloma • Oncology • Pneumococcal Infections • Psychiatry • Respiratory Diseases

Epidemiological Impact of Increasing Vaccination Coverage Rate and Re-Vaccination on Pneumococcal Disease in Older Adults in Germany. (PubMed, Vaccines (Basel)) - "Increasing the vaccination coverage rate to 60% and strategically revaccinating previously PPSV23-vaccinated adults significantly enhanced the effectiveness of pneumococcal vaccines, with V116 showing greater overall reductions in disease incidence compared to PCV20 or PPSV23."

Journal • Geriatric Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases